Guardant Health, Core Diagnostics Team Up to Offer Liquid Biopsy in India

Core Diagnostics said today that it has reached an agreement with Guardant Health AMEA under which it will market Guardant’s comprehensive liquid biopsy test, Guardant360, in India.

Guardant360 detects cell-free circulating tumor DNA from 73 genes in blood samples from advanced solid-tumor cancer patients, detecting the four major classes of alterations relevant for treatment selection: point mutations, indels, copy number alteration, and fusions/rearrangements.

Source: https://www.genomeweb.com/molecular-diagnostics/guardant-health-core-diagnostics-team-offer-liquid-biopsy-india